|
|
Article: Sanofi pasteur Delivers Investigational Pandemic Influenza Vaccine for NIAID Clinical Trials; Part of sanofi pasteur's global pandemic initiatives.
- Article from:
- PR Newswire
- Article date:
- March 10, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SWIFTWATER, Pa., March 10 /PRNewswire/ -- Sanofi pasteur (formerly Aventis Pasteur), the vaccines business of the sanofi-aventis Group , has completed production and delivered more than 8,000 investigational doses of a vaccine to protect against the H5N1 influenza strain that public health experts believe could precipitate a global pandemic. According to the World Health Organization (WHO), there have been 55 cases with 42 laboratory- confirmed deaths from the H5N1 avian influenza virus between January 28, 2004 and February 2, 2005.
The investigational doses were shipped on March 2 and 3 to the U.S. National Institute of Allergy and Infectious Diseases (NIAID), ...